BIO Wants Tighter Controls For Plant-Made Drugs, But No Fencing
Executive Summary
More details should be required for a permit to grow biotechnology-derived crops, the Biotechnology Industry Organization says in comments on a joint FDA/Department of Agriculture draft guidance on plant-made pharmaceuticals
You may also be interested in...
ProdiGene To Develop “Field Trial” Compliance Program Following Violation
ProdiGene is working with FDA and USDA to develop a compliance program as part of a settlement agreement relating to safety violations in the production of plant-made pharmaceuticals
Good “Pharming” Practices: FDA Outlines CMCs For Plant-Made Drugs
Pharmaceuticals derived from bioengineered plants should include a description of harvesting methods in the chemistry, manufacturing & controls section of NDAs and BLAs, a joint FDA/USDA 1draft guidance on plant-made pharmaceuticals says
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011